Stockscreener 앱 받기
13.64
0.29%
0.04
시간 외 거래:
13.75
0.11
+0.81%
전일 마감가:
$13.60
열려 있는:
$13.935
하루 거래량:
4.18M
Relative Volume:
0.91
시가총액:
$1.84B
수익:
-
순이익/손실:
$-191.97M
주가수익비율:
-4.3199
EPS:
-3.1575
순현금흐름:
$-159.63M
1주 성능:
+0.15%
1개월 성능:
+23.66%
6개월 성능:
+88.92%
1년 성능:
+266.67%
1일 변동 폭
$13.01
$14.02
1주일 범위
$11.56
$14.15
52주 변동 폭
$3.45
$15.40
Compass Pathways Plc Adr Stock (CMPS) Company Profile
명칭
Compass Pathways Plc Adr
전화
1-716-676-6461
주소
3RD FLOOR, 1 ASHLEY ROAD, CHESIRE
Compare CMPS vs HCA, THC, DVA, FMS, EHC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CMPS
Compass Pathways Plc Adr
|
13.64 | 1.84B | 0 | -191.97M | -159.63M | -3.1575 |
HCA
Hca Healthcare Inc
|
406.59 | 90.20B | 76.39B | 7.81B | 7.93B | 29.08 |
THC
Tenet Healthcare Corp
|
204.25 | 17.59B | 21.46B | 2.65B | 3.35B | 19.23 |
DVA
Davita Inc
|
232.80 | 14.94B | 13.84B | 1.10B | 1.49B | 10.42 |
FMS
Fresenius Medical Care Ag Adr
|
24.02 | 12.90B | 22.44B | 1.35B | 2.03B | 1.9002 |
EHC
Encompass Health Corp
|
110.16 | 10.93B | 6.07B | 793.80M | 464.40M | 5.9914 |
Compass Pathways Plc Adr Stock (CMPS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-24 | 개시 | B. Riley Securities | Buy |
| 2025-12-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-02-27 | 개시 | Stifel | Buy |
| 2024-07-23 | 개시 | RBC Capital Mkts | Outperform |
| 2024-04-01 | 개시 | Morgan Stanley | Overweight |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2022-11-21 | 재개 | Berenberg | Buy |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2021-10-29 | 개시 | Oppenheimer | Outperform |
| 2021-07-13 | 개시 | Citigroup | Buy |
| 2021-06-28 | 개시 | Maxim Group | Buy |
| 2021-05-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-04-01 | 개시 | ROTH Capital | Buy |
| 2020-10-14 | 개시 | H.C. Wainwright | Buy |
| 2020-10-13 | 개시 | Berenberg | Buy |
| 2020-10-13 | 개시 | Canaccord Genuity | Buy |
| 2020-10-13 | 개시 | Cowen | Outperform |
| 2020-10-13 | 개시 | Evercore ISI | Outperform |
모두보기
Compass Pathways Plc Adr 주식(CMPS)의 최신 뉴스
Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up - Yahoo Finance
Compass Pathways stock falls on Phase 3 trial data release - Investing.com
Compass Pathways reports 6-month data from phase 3 TRD trial - Investing.com
Compass Pathways Highlights Long-Term Data from Resistant Depression, Backs 2027 Launch Timeline - Sahm
Why is Compass Pathways stock gaining today? By Investing.com - Investing.com South Africa
Why is Compass Pathways stock gaining today? - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026? - TradingView
AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026 - TradingView
Enterprise value to EBIT forward of COMPASS Pathways Plc Sponsored ADR – MUN:5Y6 - TradingView
Compass Pathways stock hits 52-week high at 14.77 USD By Investing.com - Investing.com South Africa
Compass Pathways stock hits 52-week high at 14.77 USD - Investing.com
COMPASS Pathways Plc Sponsored ADR Actuals & Estimates (NASDAQ:CMPS) - TradingView
Compass Pathways earnings on deck as psychedelic approval nears - Investing.com
Why is Compass Pathways stock surging 9% today? By Investing.com - Investing.com India
Why is Compass Pathways stock surging 9% today? - Investing.com
Compass Pathways stock hits 52-week high at 12.48 USD By Investing.com - Investing.com South Africa
Compass Pathways stock hits 52-week high at 12.48 USD - Investing.com
Compass Pathways elects Kathleen Tregoning to board By Investing.com - Investing.com South Africa
Compass Pathways elects Kathleen Tregoning to board - Investing.com
CMPSCompass Pathways Plc ADR Stock Price and Quote - Finviz
COMPASS Pathways Plc Q1 2026 Earnings: Narrower Loss Provides Hope Amid Pre-Revenue StageLow Growth Earnings - Newser
Wolfe Research initiates Compass Pathways stock with outperform rating - Investing.com
Compass Pathways stock hits 52-week high at 11.65 USD - Investing.com
Compass Pathways stock hits 52-week high at 11.65 USD By Investing.com - Investing.com India
Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins - Yahoo Finance
Why LiveRamp Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket - Sahm
Is Compass Pathways (CMPS) outperforming other medical stocks this year? - MSN
Compass Pathways Reports Strong Q1 Results, Shares Surge - Sahm
Why COMPASS Pathways (CMPS) Is Up 13.1% After FDA Fast-Track Moves For COMP360 Profit Shift - Sahm
Compass Pathways stock hits 52-week high at 10.22 USD - Investing.com India
Compass Pathways Q1 Earnings Call Highlights - Barchart.com
Compass Pathways stock surges 8% on beating estimates as FDA accelerates review - Investing.com India
Compass Pathways stock surges 8% on beating estimates as FDA accelerates review By Investing.com - Investing.com South Africa
What makes COMPASS Pathways PLC sponsored ADR (CMPS) a strong momentum stock: Buy now? - MSN
How much upside is left in COMPASS Pathways (CMPS)? Wall Street analysts think 136% - MSN
Compass Pathways earnings on deck as psychedelic approval nears By Investing.com - Investing.com South Africa
Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Compass Pathways Plc Adr (CMPS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.88%
0.24%
자본화:
|
볼륨(24시간):